In yet another twist in a complicated tale, Health Canada has reinstated approval of a rare disease drug after the manufacturer of a rival medicine claimed the regulator had originally issued an “incorrect and unreasonable” endorsement.
The move came after Canada’s Federal Court earlier this month quashed the approval for Ruzurgi, which is used to treat people with a rare neuromuscular disorder called Lambert-Eaton myasthenic syndrome, or LEMS. The medicine is marketed by Jacobus Pharmaceuticals, a small, family run company, although a competitor, Catalyst Pharmaceuticals (CPRX), has sought to push back the approval until 2028.
This blog is for information purposes only. The content is not intended as medical advice, diagnosis, or treatment. Should you have a medical or dermatological problem, please consult with your physician. None of the information or recommendations on this website should be interpreted as medical advice.
All product reviews, recommendations, and references are based on the author’s personal experience and impressions using the products. All views and opinions are the author’s own.
This blog post may contain affiliate links. An affiliate link means we may earn a commission if you click on a link and make a purchase, without any extra cost to you.
Please see our Disclaimer for more information.